Vivani Medical (Nasdaq:VANI) today announced third-quarter earnings results that included timeline updates on its semaglutide implant. The Alameda, California-based company develops NanoPortal technology, which steadily delivers medication over extended periods of time. Vivani aims to guarantee correct patient doses while avoiding potential safety concerns around fluctuating drug release profiles. It can also deliver large hydrophilic […]
Vivani Medical
Vivani prices $15.7M offering
Vivani Medical (Nasdaq:VANI) announced that it priced a best efforts registered direct offering of 6 million shares of common stock. The Alameda, California-based company priced the shares at $1.62 apiece. It also announced a concurrent private placement of more than 3.7 million shares of common stock at the same price. Gregg Williams, the company’s board […]
Vivani sets date for neuromod spin-off as focus turns to drug delivery implant
Vivani Medical (Nasdaq:VANI) announced today that it set a record date for the approved spin-off of its Cortigent subsidiary. In May, the Alameda, California-based company announced plans to spin off Cortigent, its division developing brain implants. The company wants to create two focused companies dedicated to driving current and future value in their respective therapeutic […]
Vivani closes $10M financing, advances GLP-1 implant
Vivani Medical (Nasdaq:VANI) announced that it brought in $10 million in equity financing as it progresses its drug delivery technology. Alameda, California-based Vivani develops NanoPortal technology, which steadily delivers medication over extended periods of time. The company aims to guarantee correct patient doses while avoiding potential safety concerns around fluctuating drug release profiles. It can also […]
Vivani files with SEC to spin off neurostim business, focus on drug delivery implants
Vivani Medical (Nasdaq:VANI) announced today that it filed a Form 10 registration statement with the SEC to spin off its neurostimulation unit. The company said earlier this year that it plans to spin off Cortigent, a division that develops brain implants. The company wants to create two focused companies dedicated to driving current and future […]
Vivani reports first human GLP-1 implant for weight loss in adults
Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 clinical trial. This news comes just one day after Vivani announced plans to spin off its neurostimulation business to focus on its GLP-1 implants. The company also announced full enrollment in LIBERATE-1, achieved in just four weeks after the […]
Vivani to spin out neurostim business, focus on GLP-1 implant
Vivani Medical (Nasdaq:VANI) announced today that it plans to spin off Cortigent, a division that develops brain implants. The company wants to create two focused companies dedicated to driving current and future value in their respective therapeutic areas. Vivani aims to continue advancing its miniature GLP-1 therapeutic implants. The spin-off would enable Cortigent to continue […]
Vivani Medical initiates first-in-human GLP-1-eluting implant study
Vivani Medical (Nasdaq:VANI) announced today that it initiated screening and enrollment for a first-in-human trial of its GLP-1 implant. The company initiated its LIBERATE-1 trial at two centers in Austrlalia. It will evaluate the miniature GLP-1 (exenatide) implant in obese and overweight subjects. This study follows FDA approval for an investigational new drug (IND) application for […]
Vivani can begin first-in-human GLP-1 implant trial in Australia following regulatory approval
Vivani Medical (Nasdaq:VANI) today announced that Australian authorities approved a first-in-human clinical trial for its subdermal GLP-1 implant. The LIBERATE-1 trial will evaluate the miniature GLP-1 (exenatide) implant in obese and overweight subjects. This follows FDA approval for an investigational new drug (IND) application for the company’s implant in June. The FDA lifted the clinical hold […]
Vivani expects to start long-term GLP-1 implant trial this year
Vivani Medical (Nasdaq:VANI) today announced that it expects to initiate the first clinical study of its long-term GLP-1 implant this year. The company anticipates a fourth-quarter start for its NPM-115 program in Australia, pending regulatory clearance there. This program looks at the investigational six-month GLP-1 implant for chronic weight management. The company intends to evaluate […]
